Avenue Therapeutics, which is developing an IV formulation of the opioid tramadol, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The New York, NY-based company was founded in 2015 and plans to list on the Nasdaq under the symbol ATXI. Avenue Therapeutics filed confidentially on March 28, 2017. Raymond James is the sole bookrunner on the deal. No pricing terms were disclosed.
